Zeltia S.A.

04.04.2006 – 08:35
PharmaMar Highlights Aplidin(R) Results at AACR
Washington D.c. (ots/PRNewswire) - PharmaMar today announces the presentation of five posters highlighting advances with three of its compounds at the 97th Annual Meeting of the American Association for Cancer Research (AACR), taking place in Washington from 1-5 April 2006. The posters include results from preclinical research on Aplidin(R), Zalypsis(R) and PM02734. PharmaMar's highlights from this year's AACR ...
mehr
23.06.2005 – 09:24
Zeltia Raises EUR 65 Million Through Institutional Placing
Madrid (ots/PRNewswire) - Zeltia S.A.(ZEL SM; ZEL.MC), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per share. This transaction is one of the four largest executed in European biotech in the last four years. The funds raised will be used ...
mehr